Pulmonary Embolism

Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation insights from ROCKET AF – Fingerprint — the UWA Profiles and Research Repository Sort by Weight Alphabetically Medicine & Life Sciences Rivaroxaban 100% Atrial Fibrillation 67% Heart Failure 55% Safety 44% Stroke 28% Warfarin 26% Embolism 17% Hemorrhage 16% Factor Xa […]

Notes to editor ESC Press OfficeTel: +33 (0) 7 8531 2036Email: [email protected] Follow us on Twitter @ESCardioNews  The hashtag for ESC Congress 2021 is #ESCCongress. This press release accompanies both a presentation and an ESC press conference at ESC Congress 2021. It does not necessarily reflect the opinion of the European Society of Cardiology. […]

Xarelto (rivaroxaban) The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the US Food and Drug Administration (FDA) has approved an expanded peripheral arterial disease (PAD) indication for the Xarelto (rivaroxaban) vascular dose (2.5mg twice daily plus aspirin 100mg once daily) to include patients following recent lower-extremity revascularisation (LER) due to symptomatic PAD. The […]

Rivaroxaban is the first and only therapy indicated for both coronary artery disease and peripheral artery disease. Officials with the FDA have approved an expanded indication for rivaroxaban (Xarelto; Janssen) plus aspirin for the treatment of patients following lower-extremity revascularization (LER) due to symptomatic peripheral artery disease (PAD). According to a press release, rivaroxaban is […]

The effect of renal impairment (RI) on risk of bleeding and recurrent thrombosis in cancer patients treated with direct oral anticoagulants for venous thromboembolism (VTE) is undefined. We run a prespecified analysis of the randomized Caravaggio study to evaluate the role of RI as risk factor for bleeding or recurrence in patients treated with dalteparin […]

This article was originally published here Mayo Clin Proc. 2021 Aug 20:S0025-6196(21)00435-3. doi: 10.1016/j.mayocp.2021.04.026. Online ahead of print. ABSTRACT OBJECTIVE: To compare the bleeding risk in patients with gastrointestinal (GI) cancer with that in patients with non-GI cancer treated with anticoagulation for acute cancer-associated venous thromboembolism (Ca-VTE). PATIENTS AND METHODS: Consecutive patients with Ca-VTE seen […]

This article was originally published here J Surg Res. 2021 Aug 17;268:432-439. doi: 10.1016/j.jss.2021.06.074. Online ahead of print. ABSTRACT BACKGROUND: Several studies have demonstrated that low-molecular weight heparin (LMWH) is superior to unfractionated heparin (UFH) in trauma patients. The superiority of either one has not been established for the elderly. In this study, we compared […]

To identify the incidence of venous thromboembolism (VTE) risk factors, postoperative VTE, and to assess the morbidity of perioperative pharmacologic VTE prophylaxis in men undergoing inflatable penile prosthesis (IPP) surgery.We retrospectively reviewed 215 patients undergoing IPP surgery between July 2017 and June 2019. Univariate and multivariate statistical analyses were performed to assess pre-operative Caprini risk […]

MANHASSET, N.Y.–(BUSINESS WIRE)–Throughout the pandemic, the medical community witnessed an increased risk for major blood clotting and death in patients with coronavirus disease 2019 (COVID-19). The Feinstein Institutes for Medical Research’s Alex C. Spyropoulos, MD, will reveal during a “Latest Science” presentation at ESC Congress 2021, organized by the European Society of Cardiology (ESC) clinical […]

A blood clot is a semisolid clump of blood that forms inside a blood vessel. Research shows that your legs are the most common place for a blood clot to form. Being immobile for long periods, damage to the lining of your blood vessels, and changes in the chemistry of your blood can contribute to […]

An early switch from heparin to dabigatran, following standard clinical assessment, was both safe and effective in patients with intermediate-risk pulmonary embolism, according to study results published in Lancet Hematology. Although research conducted in the past decade has brought advances to anticoagulation treatment, including the development of direct oral anticoagulants (DOACs), it is unclear the […]

Nicholas Govsyeyev presents during SVS VAM 2021 “A strategy of adding rivaroxaban 2.5mg twice daily to aspirin should be considered after lower extremity bypass regardless of conduit type,” concluded Nicholas Govsyeyev (University of Colorado, Aurora, USA) during the William J von Liebig Forum at the Society for Vascular Surgery’s Vascular Annual Meeting (SVS VAM 2021; […]

Although non-vitamin K antagonists oral anticoagulants (NOACs) are effective in stroke prevention, the risk of major gastrointestinal (GI) bleeding could affect the safety of patients in treatment. A recent study compared the risk of stroke and systemic embolism (SE) and major bleeding among patients with nonvalvular atrial fibrillation (NVAF) and high risk of GI bleeding […]

This article was originally published here Expert Rev Clin Pharmacol. 2021 Aug 17:1-6. doi: 10.1080/17512433.2021.1964359. Online ahead of print. ABSTRACT PURPOSE: We aimed to investigate the clinical performance of edoxaban for the treatment of pulmonary embolism (PE) in hospitalized COVID-19 patients. METHODS: We conducted a retrospective analysis selecting hospitalized patients with COVID-19 admitted to our […]

MONDAY, Aug. 16, 2021 (HealthDay News) — Therapeutic-dose anticoagulation with heparin does not improve outcomes for critically ill patients with severe COVID-19, but it is beneficial for patients who are not critically ill, according to two studies published online Aug. 4 in the New England Journal of Medicine. Ewan C. Goligher, M.D., Ph.D., from the […]

A breakthrough in the treatment of vaccination blood clots has been made by UK scientists. UK scientists may have made a CORONAVIRUS breakthrough by discovering a potential therapy for blood clotting in the brain after vaccination. For the vast majority of people, the COVID-19 vaccine is quite safe. However, there have been a few occurrences […]

MONDAY, Aug. 16, 2021 (HealthDay News) — Therapeutic-dose anticoagulation with heparin does not improve outcomes for critically ill patients with severe COVID-19, but it is beneficial for patients who are not critically ill, according to two studies published online Aug. 4 in the New England Journal of Medicine. Ewan C. Goligher, M.D., Ph.D., from the […]

For older adults with atrial fibrillation, apixaban is associated with lower rates of adverse events than warfarin across all frailty levels, according to a study published online in the Annals of Internal Medicine. Dae Hyun Kim, MD, MPH, ScD, from Harvard Medical School in Boston, and colleagues examined outcomes for Medicare beneficiaries with atrial fibrillation […]